#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Type IIa hyperlipidaemia Osteogenesis imperfecta Henoch-Schonlein purpura nephritis Atypical haemolytic uraemic syndrome Gaucher's disease type III Chronic hepatitis B Anal fistula Frontotemporal dementia Prader-Willi syndrome Colitis ulcerative Autologous haematopoietic stem cell transplant Non-Hodgkin's lymphoma unspecified histology indolent Interstitial lung disease Ependymoma Aplastic anaemia More trials…

    Learn about Rare Diseases

    Cholangitis sclerosing – Trials in Disease Myxofibrosarcoma – Life with Disease Glycogen storage disease type II – Trials in Disease Systemic mastocytosis – Treatment KBG syndrome – Treatment Haemophagocytic lymphohistiocytosis – Diagnostics X-linked lymphoproliferative syndrome – Basic Information Rett syndrome – Diagnostics Antithrombin III deficiency – Basic Information Hereditary hypophosphataemic rickets – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Linsitinib Lazertinib Brivaracetam GAXILOSE Valproate Semisodium Interferon Alfa AP31969 SULFATE Azd4831 Casirivimab N-Acetylhistidine Isoleucine Efgartigimod Alfa Mepivacaine Hydrochloride Gad20-209-Fsp-A1 Fenfluramine Hydrochloride Eribulin Tramadol VHB937 Petrelintide Clindamycin Hydrochloride More therapies…

    Learn about Your Condition

    Pulmonary vascular disorder Paraganglion neoplasm Polymyositis Pterygium Primary hyperoxaluria Postpartum haemorrhage Appendicitis perforated Hypotension Hypocalcaemia Milk allergy Neuropathy peripheral Cutibacterium acnes infection Procedural anxiety Anogenital dysplasia Paget's disease of the vulva More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinikum Nuernberg

Klinikum Nuernberg

Pmuwkefyxmlbscakgousxhdenz 1m Suv Jcmjsqqco Nhrdoruvx 9apqoa Gauprsg

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Docetaxel
    • Durvalumab
    Germany Spain

  • Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Dexamethasone
    • Pomalidomide
    Germany

  • QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute promyelocytic leukaemia
    Investigated Drugs:
    • Arsenic Trioxide
    France Germany Italy Poland Romania Spain

  • AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • AZD0120
    • Bortezomib
    • Carfilzomib
    France Germany Italy Norway Poland Spain

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    • Pembrolizumab
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    Czechia Denmark France Germany Hungary Italy +3

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Carboplatin
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    • Small cell lung cancer
    • Small cell lung cancer metastatic
    Investigated Drugs:
    • BNT327
    • Atezolizumab
    • Carboplatin
    France Germany Italy The Netherlands Poland Romania +1

  • A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    Austria Belgium Denmark Estonia Finland Germany +8

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Ireland +5
1 2 3 … 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!